Status:
COMPLETED
The Effects of the Dietary Supplement CardioFlex Q10 on Reducing Cardiovascular Disease Risk Factors in Adults
Lead Sponsor:
University of Manitoba
Conditions:
Cardiovascular Diseases
Cardiovascular Abnormalities
Eligibility:
All Genders
30-65 years
Phase:
NA
Brief Summary
Cardiovascular diseases (CVD), primarily heart disease and stroke, are the leading causes of death and prescription drug use in Canada. Research on certain dietary supplements looks promising as a way...
Detailed Description
The purpose of this study is to determine whether or not daily supplementation with the dietary supplement CardioFlex Q10 for 90 days can reduce cardiovascular risk factors in healthy adults. The heal...
Eligibility Criteria
Inclusion
- Age 30-65
- An accelerated plethysmograph (APG) type (biological age of arteries) of D, E, F or G and/or a high density lipoprotein (HDL) to total cholesterol (TC) ratio of ≤24 percent
Exclusion
- Have used prescription cholesterol or blood pressure medication in the last 3 months
- Perform more then 150 minutes of moderate to rigorous activity per week
- Pregnant or planning on getting pregnant during the study period
Key Trial Info
Start Date :
November 6 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2020
Estimated Enrollment :
69 Patients enrolled
Trial Details
Trial ID
NCT03826914
Start Date
November 6 2018
End Date
August 1 2020
Last Update
October 29 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Richardson Centre for Functional Foods and Nutraceuticals
Winnipeg, Manitoba, Canada, R3T 6C5